NCT05141708View on ClinicalTrials.gov

Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m

CompletedOBSERVATIONAL
Enrollment

33

Participants

Timeline

Start Date

December 17, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Metastatic Breast CancerBreast Neoplasms
Interventions
DRUG

Talazoparib

Receipt of talazoparib as treatment for HER2-negative metastatic breast cancer with germline BRCA1/2 mutations anytime between January 1, 2018 and September 30, 2020

Trial Locations (1)

10017

Pfizer Inc., New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05141708 - Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m | Biotech Hunter | Biotech Hunter